We are live on ! Find out more
BLCO icon

Bausch + Lomb

18.04 USD
-0.10
0.55%
At close Updated Sep 4, 4:00 PM EDT
Pre-market
After hours
18.04
0.00
0%
1 day
-0.55%
5 days
6.06%
1 month
8.15%
3 months
17.52%
6 months
-0.06%
Year to date
8.81%
1 year
23.65%
5 years
-9.8%
10 years
-9.8%
 

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 21.1%
Neutral 78.9%
Negative 0%
Neutral
Business Wire
5 days ago
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting.
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Neutral
Business Wire
6 days ago
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p.
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Positive
Zacks Investment Research
13 days ago
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
Neutral
Seeking Alpha
13 days ago
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Neutral
MarketBeat
14 days ago
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Neutral
PRNewsWire
1 month ago
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Neutral
Business Wire
1 month ago
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c.
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Neutral
Seeking Alpha
1 month ago
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
Bausch + Lomb Q2 Earnings Call Highlights
Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity supported margin expansion and stronger cash generation.
Bausch + Lomb Q2 Earnings Call Highlights
Positive
Zacks Investment Research
1 month ago
Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates
Price charts implemented using Lightweight Charts™